Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected Individuals
Open Access
- 15 February 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (4) , 482-490
- https://doi.org/10.1086/367569
Abstract
The underlying mechanisms of several bone disorders in human immunodeficiency virus (HIV)–infected persons and any relation to antiretroviral therapy have yet to be defined. A longitudinal study was conducted to estimate the prevalence of osteopenia or osteoporosis in HIV-infected persons; to assess bone mineralization, metabolism, and histomorphometry over time; and to evaluate predisposing factors. A total of 128 patients enrolled the study, and 93 were observed for 72 weeks. “Classic” risk factors (low body mass index, history of weight loss, steroid use, and smoking) for low bone mineral density (BMD) and duration of HIV infection were strongly associated with osteopenia. There was a weak association between low BMD and receipt of treatment with protease inhibitors; this association disappeared after controlling for the above factors. Markers of bone turnover tended to be elevated in the whole cohort but were not associated with low BMD. BMD increased slightly during follow-up. Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.Keywords
This publication has 17 references indexed in Scilit:
- Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons—2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America*Annals of Internal Medicine, 2002
- Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapyAIDS, 2001
- Osteopenia in HIV-infected patients: is it the disease or is it the treatment?AIDS, 2001
- Osteonecrosis Complicating Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2000
- Hyperlactatemia and Hepatic Abnormalities in 10 Human Immunodeficiency Virus-Infected Patients Receiving Nucleoside Analogue Combination RegimensClinical Infectious Diseases, 2000
- Fasting Hyperinsulinemia and Changes in Regional Body Composition in Human Immunodeficiency Virus-Infected WomenJournal of Clinical Endocrinology & Metabolism, 1999
- Adverse effects of reverse transcriptase inhibitorsAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997